Future Catalysts | Anticipate crucial clinical data readouts in 2025 for lupus treatments, potentially validating technology and attracting partnerships |
Market Challenges | Navigate the competitive CAR-T landscape as Adicet Bio aims to differentiate its approach in a crowded field of cell therapy developers |
Financial Footing | Strong cash position of $125 million extends runway into Q4 2026, supporting ongoing clinical trials despite absence of current revenue |
Pipeline Promise | Adicet Bio's innovative gamma-delta T cell therapies for autoimmune diseases and cancer show potential, with clinical trials underway for multiple indications |
Metrics to compare | ACET | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACETPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −3.8x | −0.5x | |
PEG Ratio | −0.04 | −0.21 | 0.00 | |
Price / Book | 0.5x | 2.6x | 2.6x | |
Price / LTM Sales | - | 5.9x | 3.2x | |
Upside (Analyst Target) | 163.0% | 298.5% | 50.6% | |
Fair Value Upside | Unlock | 18.2% | 7.1% | Unlock |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.